Decapeptyl · Prostate cancer - 11.25mg subcutaneous formulation
Development and Regulatory status
Apr 19 · Ipsen withdraws a MAA to the EMA for Decapeptyl 3M subcutaneous administration. Due to the overwhelming uncertainty in the current political environment and the unknown impact on supply and distribution of medicine, Ipsen does not feel it is an appropriate time to launch a new route of administration. Ipsen will continue to monitor the political environment and reassess the application when it feels appropriate for the UK market .
Synthetic decapeptide analogue of natural gonadotropin-releasing hormone analogue. Given 3-monthly.
The age-standardised incidence of prostate cancer in the UK in 2014 was 175 per 100,000 population
Prostate cancer - 11.25mg subcutaneous formulation